Hemp Therapies Wiki / Cannabinoids & Plant Chemistry

CBC (Cannabichromene) and CBDA

CBC (cannabichromene) and CBDA (cannabidiolic acid) are two cannabinoids distinct from CBD and THC: CBC is a separate minor cannabinoid, and CBDA is the raw, acidic precursor form of CBD itself.

CBC’s Origin and Receptor Profile

CBC’s biosynthesis runs through the polyketide and mevalonate/methylerythritol-phosphate pathways: the enzyme CBC synthase (CBCAS) converts CBGA (cannabigerolic acid) into CBCA (cannabichromenic acid), which then decarboxylates into CBC. CBC is described as the fourth most abundant constituent in many cannabis chemovars, while remaining significantly understudied compared to THC and CBD. It is non-intoxicating and does not produce the central effects associated with THC.

CBC functions as a CB2 receptor agonist, and research indicates it is selective for CB2 over CB1 — a distinction from THC among the major cannabinoids. Among cannabinoids studied, CBC is described as the most potent known activator of the transient receptor potential ankyrin (TRPA1) channel, with a reported EC50 of 90 nM. In one pharmacokinetic study, CBC was absorbed rapidly in an animal model, reaching peak concentration (tmax) between 1.5 and 3 hours, and did not accumulate in plasma after 14 days of repeated dosing. In that same study, CBC brain concentrations measured on day 14 were higher than on day 1 across multiple tested doses, suggesting possible accumulation specifically in brain tissue with repeated dosing. In separate preclinical mouse studies, CBCA — the acidic precursor form of CBC — showed no measurable conversion into decarboxylated CBC in vivo.

CBDA as CBD’s Raw-Plant Precursor

CBDA is the acidic, raw-plant form of CBD; decarboxylation, typically via heat, converts CBDA into CBD. In one mouse study, CBD was detected at only about 0.5% of the administered CBDA concentration in plasma, indicating only partial in vivo conversion from the acidic to the neutral form under those conditions. CBDA brain penetration in that study was greater when administered in a Tween-based vehicle compared with an oil-based vehicle. In clinical vaporization studies, measured CBDA concentrations were significantly lower than CBD concentrations, an effect attributed to heat-induced decarboxylation during vaporization. In one dog pharmacokinetics study, CBDA absorption was reported as roughly twice that of CBD across three tested formulations, and CBDA has also been reported to show higher bioavailability than CBD in studies using Macaca fascicularis (a primate model). Pharmacokinetic parameters for CBD, CBG, CBC, and their acidic forms (CBDA, CBGA, CBCA) are described in the research literature as highly variable, depending on dose, formulation, administration route, and diet.

CBC and CBDA on Product Labels

Multi-cannabinoid research formulations combining CBC with CBD and THC have been studied; one clinical formulation contained 120 mg CBD, 5.4 mg THC, and 6.6 mg CBC. A preclinical dog study used formulations with variable cannabinoid ratios, ranging from approximately 2 parts CBD to 0.1 parts THC to 0.4 parts CBC, up to 10 parts CBD to 0.5 parts THC to 2.0 parts CBC. One dog-study formulation contained 28 mg/mL CBD, 29 mg/mL CBDA, 1 mg/mL THC, 0.8 mg/mL THCA, 0.7 mg/mL CBGA, and 1.3 mg/mL CBC, illustrating how acidic and neutral cannabinoid forms can appear together on a single lab breakdown. A broad-spectrum CBD distillate may separately list CBD alongside minor cannabinoids such as CBG, CBC, and CBDA; such a distillate commonly contains approximately 87–95% CBD and at least 5% additional minor cannabinoids.

Summary

CBC is a distinct, CB2-selective minor cannabinoid produced through its own biosynthetic pathway from CBGA, while CBDA is simply the acidic form CBD takes before decarboxylation converts it. Both appear alongside CBD on lab reports for full- and broad-spectrum products, and both remain less studied than CBD or THC.